Staidson BioPharm(SZ:300204) Sou Hu Cai Jing·2025-10-27 16:59Core Viewpoint - Shuyou Shen (300204) plans to issue shares to specific investors to raise up to 1.253 billion yuan for innovative drug research and working capital, following approval from the board and shareholders [3][5]. Group 1: Financial Performance - As of December 31, 2024, the company's total consolidated assets amounted to 1,149.61 million yuan, with total liabilities of 232.85 million yuan and equity attributable to shareholders of 929.23 million yuan [2]. - For the fiscal year 2024, the company reported a consolidated revenue of 324.82 million yuan and a net loss of 147.73 million yuan, with a negative cash flow from operating activities of 63.68 million yuan [2]. - The company has experienced continuous net losses over the past three years, with a net loss of 24.64 million yuan in the first half of 2025 [4]. Group 2: Stock Issuance Details - The planned share issuance will not exceed 143,331,766 shares, representing 30% of the total share capital prior to the issuance, with a minimum issuance price set at 80% of the average trading price over the previous 20 trading days [3][5]. - The funds raised will be allocated as follows: 883 million yuan for clinical research and registration of innovative drugs (BDB-001, STSA-1002, STSP-0902) and 370 million yuan for working capital [5]. - The issuance is subject to approval from the Shenzhen Stock Exchange and registration with the China Securities Regulatory Commission [4][5]. Group 3: Market Activity - On October 27, 2025, Shuyou Shen's stock closed at 34.13 yuan, with a trading volume of 342,800 shares and a turnover of 1.189 billion yuan [1]. - The net outflow of funds from major investors on the same day was 57.71 million yuan, while retail investors saw a net inflow of 95.75 million yuan [2][4].